Clinical Trials
56 trialsCD22-CAR T Cells in Children and Young Adults With B Cell Malignancies
Stanford University
Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
National Cancer Institute (NCI)
Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma
City of Hope Medical Center
FT819 in Subjects With B-cell Malignancies
Fate Therapeutics
ALPHA
Allogene Therapeutics
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
St. Jude Children's Research Hospital
Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
UNC Lineberger Comprehensive Cancer Center
Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma
UNC Lineberger Comprehensive Cancer Center
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine
University of Arizona
Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma
Case Comprehensive Cancer Center
Axi-cel in CNS Lymphoma
Dana-Farber Cancer Institute
Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL
University Health Network, Toronto
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
National Institutes of Health Clinical Center (CC)
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
Caribou Biosciences, Inc.
FT516 in Subjects With Advanced Hematologic Malignancies
Fate Therapeutics
FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies
Fate Therapeutics
Combination of CAR-DC Vaccine and ICIs in Malignant Tumors
Chinese PLA General Hospital
A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Bristol-Myers Squibb
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Fate Therapeutics
Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies
The Affiliated People's Hospital of Ningbo University
V+DA-EPOCH-R
Weill Medical College of Cornell University
CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies
Loyola University
Treatment of Macroglobulinemic Lymphoma With 2CdA, Cyclophosphamide and Rituximab
M.D. Anderson Cancer Center
Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas
National Institutes of Health Clinical Center (CC)
VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies
Icahn School of Medicine at Mount Sinai
Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention
M.D. Anderson Cancer Center
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic Cancer
Jonsson Comprehensive Cancer Center
Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia
Case Comprehensive Cancer Center
Infusion of Allogeneic, 3rd Party CD19-specific T Cells
M.D. Anderson Cancer Center
ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer
National Institutes of Health Clinical Center (CC)
Gene Therapy-Treated Stem Cells in Treating Patients Undergoing Stem Cell Transplant for Intermediate-Grade or High-Grade AIDS-Related Lymphoma
City of Hope Medical Center
Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation
University of Maryland, Baltimore
Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source
University of Pittsburgh
Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
M.D. Anderson Cancer Center
Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases
Masonic Cancer Center, University of Minnesota
T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer
Masonic Cancer Center, University of Minnesota
Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma
Alliance for Clinical Trials in Oncology
A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms
Seagen Inc.
Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
Massachusetts General Hospital
Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy
Dana-Farber Cancer Institute
Azacitidine With Rituximab, Vincristine, and Cyclophosphamide in Refractory Lymphoma
University of Kentucky
CD19-redirected Autologous Cells (CAR-CD19 T Cells)
RenJi Hospital
Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies
Shenzhen Second People's Hospital
A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL)
Emory University
Combination Chemotherapy in Treating Children With Stage III or Stage IV Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia
Children's Oncology Group
Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Alemtuzumab and Combination Chemotherapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Peripheral T-Cell Lymphoma
National Cancer Institute (NCI)
Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Northwestern University
T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies
National Institutes of Health Clinical Center (CC)
Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies
M.D. Anderson Cancer Center